← All companies
About this company
Our platform provides an innovative AI solution that enables early diagnosis of Alzheimers disease for medical institutions,including hospitals, clinics, medical centers, and memory centers.Traditional early diagnosis methods, which require the injection of a radioactive component (FDG-PET), are invasive. The platforms first proprietary product is based on the scientific research of Prof. Sven Haller, which demonstrates that Arterial Spin Labeling (ASL), an emerging clinical MRI technique, can detect blood flow in the brain. Due to the correlation between blood flow and glucose metabolism in blood flow and glucose metabolism in the brain, ASL may serve as an alternative to the established FDG-PET with first application for Dementia and possible applications for Vascular diseases, onco.